- Home
- CNTA vs TSLX Comparison
CNTA vs TSLX Comparison
Compare CNTA & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTA | TSLX |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.2B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNTA | TSLX |
|---|---|---|
| Price | $23.55 | $21.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $37.70 | $23.50 |
| AVG Volume (30 Days) | ★ 1.1M | 482.3K |
| Earning Date | 11-05-2025 | 02-12-2026 |
| Dividend Yield | N/A | ★ 9.46% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.04 |
| Revenue | $15,000,000.00 | ★ $464,512,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.61 |
| Revenue Growth | ★ 118.88 | N/A |
| 52 Week Low | $9.60 | $18.58 |
| 52 Week High | $30.58 | $25.17 |
Technical Indicators
Market Signals| Indicator | CNTA | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 48.17 |
| Support Level | $24.17 | $21.18 |
| Resistance Level | $26.01 | $21.98 |
| Average True Range (ATR) | 1.09 | 0.29 |
| MACD | -0.31 | -0.02 |
| Stochastic Oscillator | 1.79 | 32.79 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.